CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increasing investments in neuroscience research
4.1.2. Growth in the pharmaceutical and biotechnology industries
4.2. Market Restraints & Challenges
4.2.1. Quality and cost concerns over the production of antibodies
4.2.2. Stringent regulations
4.3. Market Opportunities
4.3.1. Emerging markets
4.3.2. Increasing demand for personalised medicine
4.3.3. Growing focus on biomarker discovery
CHAPTER 5. GLOBAL NEUROSCIENCE ANTIBODIES & ASSAYS MARKET – BY
PRODUCT
5.1. Consumables
5.1.1. Reagents
5.1.1.1. Media and Sera
5.1.1.2. Stains and Dyes
5.1.1.3. Fixatives
5.1.1.4. Buffers
5.1.1.5. Solvents
5.1.1.6. Enzymes, Proteins, and Peptides
5.1.1.7. Probes
5.1.1.8. Others
5.1.2. Antibodies
5.1.2.1. Primary Antibodies
5.1.2.2. Secondary Antibodies
5.1.3. Assay Kits
5.2. Instruments
5.2.1. Immunoassay Analyzers
5.2.2. Microplate Readers
5.2.3. Other Instruments
CHAPTER 6. GLOBAL NEUROSCIENCE ANTIBODIES & ASSAYS MARKET – BY
TECHNOLOGY
6.1. Immunoassays/Immunochemistry
6.1.1. Enzyme-Linked Immunosorbent Assay (Elisa)
6.1.2. Western Blotting
6.1.3. Other Immunoassay Technologies
6.2 Molecular Diagnostics
6.3 Clinical Chemistry
6.4 Others
CHAPTER 7. GLOBAL NEUROSCIENCE ANTIBODIES & ASSAYS MARKET – BY
APPLICATION
7.1. Drug Discovery & Development
7.2. Research
7.3. In Vitro Diagnostics
CHAPTER 8. GLOBAL NEUROSCIENCE ANTIBODIES & ASSAYS MARKET – BY
END USER
8.1. Pharmaceutical & Biotechnology Companies
8.2. Academic & Research Institutes
8.3. Hospitals & Diagnostics Centers
CHAPTER 9. GLOBAL NEUROSCIENCE ANTIBODIES & ASSAYS MARKET - BY
GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL NEUROSCIENCE ANTIBODIES & ASSAYS MARKET -
COMPANY PROFILES
10.1. Merck Group
10.2. Cell Signaling Technology, Inc.
10.3. Genscript Corporation
10.4. Rockland Immunochemicals, Inc.
10.5. BioLegend
10.6. Santa Cruz Biotechnology, Inc.
10.7. Tecan Group Ltd
10.8. Roche Holdings AG
10.9. Siemens AG
10.10. Bio-Rad Laboratories
10.11. Abcam plc
10.12. Thermo Fisher Scientific Company
CHAPTER 11. GLOBAL NEUROSCIENCE ANTIBODIES & ASSAYS MARKET -
COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
